COMPANY PROFILE / #1515
Adaptyv
Lausanne, SwitzerlandVenture Capital-Backed
OVERVIEW
Developer of an automated protein validation and experimental data management platform designed for protein research and biological design workflows. The company's platform helps to submit protein sequences, select experimental assay types, manage wet-lab experiments, track experiment progress, access analyzed and labeled experimental datasets, export raw results, integrate data through APIs, and support iterative model development through automated laboratory testing and protein synthesis, enabling biotechnology, pharmaceutical, and protein engineering teams to obtain experimental validation data and manage research workflows.
已融资51.21
最新估值218.00
员工数25
成立年份2020
公司概况
- Companies
- Adaptyv
- Description
- Developer of an automated protein validation and experimental data management platform designed for protein research and biological design workflows. The company's platform helps to submit protein sequences, select experimental assay types, manage wet-lab experiments, track experiment progress, access analyzed and labeled experimental datasets, export raw results, integrate data through APIs, and support iterative model development through automated laboratory testing and protein synthesis, enabling biotechnology, pharmaceutical, and protein engineering teams to obtain experimental validation data and manage research workflows.
- Website
- www.adaptyvbio.com
- HQ Location
- Lausanne, Switzerland
- Year Founded
- 2020
- Keywords
- ai in healthcare, antibodies test, biotechnology center, biotechnology device, computational system, nanofluidic sample, protein engineering technology, synthetic biology study
- Competitors
- ATUM (Biotechnology), Takara Bio USA, Mayflower Bioscience, Cell Technology, BioVision, Integral Molecular, Novus Biologicals, Assay Biotech, BioLegend, BPS Bioscience, Eurofins Calixar, Creative BioMart, DiaCarta, Immunomic Therapeutics, Apexigen
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 51.21
- First Financing Date
- 01-Jan-2020
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 26-Aug-2026
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 40.00
- Last Financing Valuation
- 218.00
- Last Financing Status
- Completed
- Last Known Valuation
- 218.00
- Last Known Valuation Date
- 26-Aug-2026
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 220.93
- Valuation Estimate Growth Rate
- 1.34%
- Active Investors
- ACE & Company (Geneva), ACE Ventures (Geneva), Acequia Capital, Axial (San Francisco), Biopole, byFounders, Ecole Polytechnique Federale de Lausanne, Founderful, Founderful Campus, Founders, Inc, Hawktail, Highland Europe, iGem Startups, LongGame Ventures, Neer Venture Partners, Rheingau Founders, S2S Ventures, S2S Ventures (South Africa), Unruly Capital, Venture Kick, Y Combinator
- # Active Investors
- 21
- Acquirers
- —
团队与联系人
- Employees
- 25
- Employee Growth %
- 13.64%
- Employee History
- 2026: 25, 2025: 22, 2024: 15, 2023: 14, 2022: 9, 2021: 4
- Primary Contact
- Julian Englert
- Primary Contact Title
- Co-Founder & Chief Executive Officer
- Primary Contact Email
- julian@adaptyvbio.com
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.95%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 97
- Size Multiple
- 6.25x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 86
- Majestic Referring Domains
- 244
- SimilarWeb Unique Visitors
- 1,367
- SimilarWeb Unique Visitors Change
- 57
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 6%
- Success Probability Over Time – 3 Year
- 12%
- Success Probability Over Time – 5 Year
- 22%
记录来源:public.companies · 原始序号 #1515 · 所有字段均按数据库原值展示。